Checkmate Pharmaceuticals (NASDAQ: CMPI) is a clinical stage company pursuing a novel approach to specifically activating the innate and adaptive arms of the immune system to recognize and ultimately destroy tumor cells. Checkmate Pharmaceuticals was acquired by Regeneron (NASDAQ: REGH) in 2022.
Sector: Life Sciences
CORE Diagnostics
CORE provides high-end diagnostics services for disease stratification and therapy selection. This company was acquired in December 2024.
Promentis Pharmaceuticals
Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company, is developing innovative therapies for neuropsychiatric disorders.
Cipla Health
Cipla Health focuses on developing and commercializing products in the consumer healthcare and over-the-counter categories.
Turnstone Biologics
Turnstone Biologics (NASDAQ: TSBX) is transforming patient care with a new class of targeted viral immunotherapies to fight cancer.
Eywa Pharma
Eywa is a global generic pharmaceutical company engaged in research and development, manufacture, marketing, sale, and distribution of generic finished dosage formulations.
VYNE Therapeutics
VYNE Therapeutics (NASDAQ: MNLO) is a late-stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. Formerly Menlo Therapeutics.
Xilio Therapeutics
Xilio Therapeutics (NASDAQ: XLO) is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor.
Compass Therapeutics
Compass Therapeutics (NASDAQ: CMPX) is comprehensively drugging the tumor-immune synapse with human antibodies against over 50 cell surface and soluble targets.
Orchard Therapeutics
Orchard Therapeutics (NASDAQ: ORTX) is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies. Developed LENMELDY to marketing approval in 2024. Acquired by Kyowa Kirin in 2023.